NuSep licences gels
Wednesday, 17 September, 2008
NuSep [ASX: NSP] will accept an offer to license its electrophoresis gel business.
The third party had offered to acquire NuSep's gels business outright or to license the technology.
It was decided that licensing the technology would provide the best return for shareholders, the company said.
The licensing deal should give NuSep enough money to fund this commercialisation of its MF10 and SpermSep separation instruments without any additional fund-raising, and will likely generate an ongoing royalty fee.
NuSep also supplies research grade biological products such as human IgG and albumin.
Fast-aging placentas may contribute to pre-eclampsia
Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...
BioNTech opens mRNA manufacturing facility at La Trobe
Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
